# ASCEND (CancerSEEK case-control collection)

Source: https://onco.cc/trials/ascend-cancerseek/  
OnCo record `ascend-cancerseek` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An Exact Sciences study that collected blood from people with and without cancer to develop the CancerSEEK blood test.

## Summary

ASCEND (NCT04213326) is an observational study sponsored by Exact Sciences Corporation. It collected 60 mL blood samples and medical-record data from people with and without cancer to train and test the assay. Results are posted on the registry.

The registry record, read on 29 October 2026, gives its status as completed, with 6,400 participants enrolled, a start on 18 November 2019 and primary completion on 29 January 2021.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-10-29
- Also known as: ASCEND; Ascertaining Serial Cancer Patients to Enable New Diagnostic
- Registry id: NCT04213326
- Phase: observational
- Setting: People with known or suspected cancer and people with no known cancer at US sites, giving blood to develop the CancerSEEK multi-cancer test
- Sponsor: Exact Sciences Corporation
- Enrolled: 6400

## Sources

- ClinicalTrials.gov NCT04213326: https://clinicaltrials.gov/study/NCT04213326

## Connected records

- terms: [DETECT-A: a blood test plus PET-CT to screen 10,006 women with no symptoms](https://onco.cc/terms/detect-a-study/)
- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Cancerguard](https://onco.cc/drugs/cancerguard/), [CancerSEEK](https://onco.cc/drugs/cancerseek/)
- companies: [Exact Sciences (Abbott)](https://onco.cc/companies/exact-sciences/)

---
JSON: https://onco.cc/api/v1/entities/ascend-cancerseek.json